Very Early Stage

Decided, but not sure of commercial potential and evidence required to bring to market

Very Early Stage Innovators can struggle to understand the nuance of their technology’s value proposition from the perspective of payers and end-users.

This creates challenges in defining the time and financial investment that will be required to achieve regulatory approval and market adoption, impairing the demonstration of the Return on Investment opportunity.

ASSESS brings expert insight to the description of a technology’s value proposition, its pathway to market adoption and the potential Return on Investment.

Learn more
team
Photo by Jason Goodman on Unsplash
How We Do It

Analytic approach to informing foundational decisions

At each stage of the Commercialization Journey, life sciences innovators have key questions, and analytic and decision support needs, that can be answered and provided by those with expertise in health technology assessment and health economics.

Stage based insights and methods

Insights help to inform strategy and focus evidence generation activities on those that are the most valuable, and analyses and evidence generated support communication with investors, end users and payers.

ASSESS and a global network of experts bring methods and insights from health technology assessment and economic modelling to help innovative companies make informed strategic decisions early in technology development. Innovators at the Very Early Stage can have decisions informed by Headroom, Economic Value Driver, and Evidence Mapping analyses.

  • Trial Objectives
  • Implementation Strategies
  • Study Design
  • Outcome Measures
team
Photo by Nik on Unsplash
team

Headroom Analysis

Technology commercial potential can be assessed and quantified considering the headroom for improvement of health relative to the current standard of care for a chosen clinical condition, as well as the headroom to improve the treatment cost profile and economic efficiency for target payers.

  • Prevalence/incidence
  • Burden of illness
  • Current recommended treatments (effectiveness/cost)
  • Cost and effectiveness gaps in current treatments
  • Scientific rationale and existing evidence for technology use
  • Factors affecting implementability in clinical practice
  • Issues with conducting clinical trials

Headroom analysis supports innovators to define and articulate the commercial potential and viability of clinical application for their technology.

Economic Value Drivers Identification

The economic value of technology to health systems and payers typically is driven by a limited number of variables influenced by technology, both in terms of health and cost improvement.

Economic value drivers analysis supports innovators:

  1. Clarity: Understand the most important drivers of the technology value proposition
  2. Focus: Positions to focus R&D and data collection/evidence generation activities around these key drivers
  3. Demonstration: Generate evidence in order to make the strongest case for technology adoption
team
Photo by Jitian Pan on Unsplash
team
Photo by İrfan Simsar on Unsplash

Evidence Requirement Mappings

Health care payers require specific evidence of the economic value of technology in order for procurement/adoption, scale and spread.

Evidence requirements mapping enables innovators to develop an evidence generation plan that ensures development of evidence sufficient to support commercial success:

Evidence Requirements : Early insights into the likely evidence requirements for commercialization

Duration and Cost : Likely time, cost, and probability of successfully generating evidence sufficient for adoption, scale and spread

Testimonials

What our clients say

Proton

“We enjoyed working with and recommend ASSESS. They helped us to complete an early economic analysis, including a variety of sensitivity analyses, to assist us to demonstrate that our product is extremely cost effective in our target population.”

Rory St. Clair
VP Operations
Careteam

“We are extremely satisfied with the work done and have already recommended the service to others.

This program has been invaluable to us, I can't say enough to recommend it - this kind of evidence is vital to digital health sales and incredibly hard to find. We plan to include the service in major research projects in the future to demonstrate the economic impact of our interventions.”

Rob Attwell
COO
Nura Medical

“The ASSESS project provided NURA with robust, real-world data to substantiate the health economic rationale underlying our pricing structure. This data will be instrumental in presenting our value proposition to hospital decision-makers and investors.”

Georgia Powell
Co-founder & CEO
Greenspace

“Our team was very happy with the level of thoroughness and rigor of the work and deliverables from the ASSESS team, as well as their communication. We would recommend the service to other organizations given the ease of working with the ASSESS team and the rigor of their work.”

Tanya Scarapicchia

Contact Us

Contact us to learn more about how insights from ASSESS can help your organization make informed strategic decisions that help maximize commercial success of technology in development.

Let's talk